A new treatment from Canadian researchers for progressive MS involves
Pharmaceutical grade Biotin which was found to reverse disease progression in a significant proportion of patients with progressive multiple sclerosis.This research was presented at the 68th Annual Meeting of the American Academy of Neurology.
Biotin is safe and proved to be effective throughout two years of treatment. Biotin, did not, show significant visual acuity improvement compared to placebo. High dose biotin did have some consistent double-blind phase side effects: infections, infestations and disorders involving the nervous, gastrointestinal, musculoskeletal and connective tissue systems.“This is the first time that a drug has reversed the progression of the disease in a statistically significant proportion of patients,” said Dr. Tourbah. “Almost no progression was observed in patients treated with MD1003 for 24 months, and this has never been observed before. When we compare these results to other trials in progressive MS that involved more than 6,000 patients overall, this is clearly the best effect size ever observed.”
"Among participants with nonprogressive chronic optic neuropathy, visual acuity improved in both treatment arms, and the researchers saw little difference between them at 12 months. Among patients with progressive chronic optic neuropathy, disease progression stopped in participants who switched from placebo to MD1003".
We have formulated I.V. nutrient and ozone treatments for macular degeneration and for MS that have benefitted our patients. All I.V. therapies are MD supervised and RN administered in NY.